Physician profile
Jonathan Robert Bundy
NPI 1265641203
$977.33
in general payments reported to CMS, 2019-2025
9 companies · $367 in 2025
The $367 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $30.80 · 2021: $103 · 2022: $54.61 · 2023: $28.01 · 2024: $277 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $672.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $485.41 | 2022-2025 | Infuse, Miebo, Xiidra |
| Allergan, INC. | $174.95 | 2019-2022 | |
| Glaukos Corporation | $117.94 | 2025 | Idosetr |
| Aerie Pharmaceuticals, INC. | $53.57 | 2019-2021 | |
| Rxsight INC | $44.56 | 2024 | Rxsight Contact Lens, Rxsight Injector Cartridge, Light Adjustable Lens (Lal) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $35.60 | 2019-2021 | |
| Coopervision INC. | $30.78 | 2024-2025 | Biofinity Contact Lens, Myday Contact Lens |
| Alcon Vision LLC | $21.48 | 2022 | |
| Sight Sciences, INC. | $13.04 | 2023 | Tearcare System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bundy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.